WGPlus (Archive)

We need to find an answer to this conundrum
Revenues for pharmaceutical companies need to be 'delinked' from sales of antibiotics to avoid their over-use and avert a public health crisis, says a new report from the think-tank Chatham House.   By 2050, failing to tackle antibiotic resistance could result in 10m premature deaths p.a.  Novel antibiotics to combat resistant pathogens are thus desperately needed, but market incentives are exacerbating the problem.  The current business model ‘requires high levels of antibiotic use in order to recover the costs of R&D.  But mitigating the spread of resistance demands just the opposite: restrictions on the use of antibiotics.’
Researched Links:

Chatham House:  Radical new business model for pharmaceutical industry needed to avert antibiotic resistance crisis

FCO:  The Longitude Prize: Why India should be in it to win it

Without a solution to this issue we will be, medically speaking, ‘In deep s**t’

Still time to ‘save the world’

Antibiotic Research UK

ICS.AI Webinar with the ICO: Reduce inbound contact with AI-driven customer service